I. V. Hoorebeeck

Identi ® cation and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in ® rst-line chemotherapy in advanced breast cancer

J. Klijn, M. Piccart, R. Paridaens, 2000 .

Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): results of a randomized phase II trial

M. Piccart, M. Nooij, R. Paridaens, 2000 .

Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer.

J. Klijn, M. Piccart, J. de Haes, 2000, European journal of cancer.

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.

L Biganzoli, M. Piccart, M. Nooij, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.